A company insider recently bought 10,526 shares of Concert Pharmaceuticals Inc. [CNCE]. Should You Buy?

Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Concert Pharmaceuticals Inc. shares valued at $49,998 were purchased by van Heek Christi on Jun 06. At $4.75 per share, van Heek Christi acquired 10,526 shares. The insider’s holdings grew to 25,651 shares worth approximately $0.16 million following the completion of this transaction.


3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.

Sponsored


Also, Auchincloss Thomas G purchased 6,000 shares, netting a total of over 28,500 in proceeds. Following the buying of shares at $4.75 each, the insider now holds 17,625 shares.

Before that, ALDRICH RICHARD had added 210,526 shares to its account. In a trade valued at $999,998, the Director bought Concert Pharmaceuticals Inc. shares for $4.75 each. Upon closing the transaction, the insider’s holdings increased to 210,526 shares, worth approximately $1.29 million.

As published in their initiating research note from Berenberg on December 16, 2020, Concert Pharmaceuticals Inc. [CNCE] has been a Buy and the price target has been revised to $25. This represents a 75.4% premium over Thursday’s closing price. Analysts at Jefferies started covering the stock with ‘”a Buy”‘ outlook in a report released in late March. As of October 03, 2019, H.C. Wainwright has reiterated its “Buy” rating for CNCE. Earlier on June 24, 2019, SunTrust initiated its rating. Their recommendation was “a Buy” for CNCE stock.

Analyzing CNCE’s Price Performance

On Thursday, Concert Pharmaceuticals Inc. [NASDAQ: CNCE] rose 2.50% to $6.15. The stock’s lowest price that day was $6.02, but it reached a high of $6.43 in the same session. During the last five days, there has been a surge of approximately 13.47%. Over the course of the year, Concert Pharmaceuticals Inc. shares have jumped approximately 95.24%. Shares of the company reached a 52-week high of $6.88 on 05/31/22 and a 52-week low of $2.57 on 02/24/22. A 50-day SMA is recorded $4.84, while a 200-day SMA reached $3.70. Nevertheless, trading volume fell to 1.11 million shares from 0.75 million shares the previous day.

Support And Resistance Levels for Concert Pharmaceuticals Inc. (CNCE)

According to the 24-hour chart, there is a support level at 5.97, which, if violated, would cause prices to drop to 5.79. In the upper region, resistance lies at 6.38. The next price resistance is at 6.61. RSI (Relative Strength Index) is 68.96 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at 0.86, which suggests the price will decrease in the coming days. Percent R is at 13.27%, indicating bullish price movement. Stochastics %K at selling indicates that the stock is to be held.

Is Concert Pharmaceuticals Inc. subject to short interest?

Stocks of Concert Pharmaceuticals Inc. saw a sharp rise in short interest on Jul 14, 2022 jumping by 40000.0 shares to 1.1 million. Data from Yahoo Finance shows that the short interest on Jun 14, 2022 was 1.06 million shares. A jump of 3.64% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 2.64 of the overall float, the days-to-cover ratio (short ratio) jumped to 2.64.

Which companies own the most shares of Concert Pharmaceuticals Inc. (CNCE)?

According to RA Capital Management LP filings, the company currently owns 3,033,603 shares, which is about 8.35% of the total CNCE shares outstanding. The investor’s shares have plunged by 0 from its previous 13-F filing of 3033603.0 shares. With the completion of the sale transaction, BVF Partners LP’s stake is now worth $9,485,130. Perceptive Advisors LLC reduced a 0.00% interest valued at $9.05 million while Ingalls & Snyder LLC sold a -41,150 stake. A total of -103,817 shares of Concert Pharmaceuticals Inc. were sold by Millennium Management LLC during the quarter, and -331,397 were sold by The Vanguard Group, Inc. In its current portfolio, Medical Strategy GmbH holds 850,444 shares valued at $3.58 million.

LEAVE A REPLY

Please enter your comment!
Please enter your name here